BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31845843)

  • 1. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
    Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
    Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
    Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
    Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 6. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.
    Mendiratta-Lala M; Aslam A; Maturen KE; Westerhoff M; Maurino C; Parikh ND; Sun Y; Sonnenday CJ; Stein EB; Shampain KL; Kaza RK; Cuneo K; Masch W; Do RKG; Lawrence TS; Owen D
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):704-714. PubMed ID: 34644607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
    Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
    Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
    Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.
    Zhang Y; Wang J; Li H; Zheng T; Jiang H; Li M; Song B
    Ann Transl Med; 2020 Mar; 8(6):388. PubMed ID: 32355832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
    Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
    Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
    Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
    Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.
    Cools KS; Moon AM; Burke LMB; McGinty KA; Strassle PD; Gerber DA
    Liver Transpl; 2020 Feb; 26(2):203-214. PubMed ID: 31677319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.